Sunitinib
Sunitinib (SU11248) is a multi-targeted receptor tyrosine kinase inhibitor with potent activity against VEGFR2 and PDGFRβ (IC50=80/2 nM) . It exhibits antitumor effects and is used in research on renal cell carcinoma and gastrointestinal stromal tumors, supported by both in vitro and in vivo studies.
Product Specifications
CAS Number
557795-19-4
Product Name Alternative
Apoptosis, Autophagy, cKit, c-Kit, inhibit, IRE1, Platelet-derived growth factor receptor, Mitophagy, Mitochondrial Autophagy, Inositol requiring enzyme 1, Inhibitor, FLT3, SU 11248, SU11248, SU-11248, Sunitinib, PDGFR, PDGFRβ, VEGFR2, VEGFR, Vascular endothelial growth factor receptor
Field of Research
Cardiovascular Research, Cell Biology, Pharmacology & Drug Discovery, Signal Transduction
Purity
98.00% (May vary between batches)
Solubility
Ethanol:< 1 mg/mL (insoluble or slightly soluble) ; H2O:< 1 mg/mL (insoluble or slightly soluble) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:1.25 mg/mL (3.14 mM) ; DMSO:25 mg/mL (62.74 mM)
Smiles
C (=C\1/C=2C (NC1=O) =CC=C (F) C2) \C3=C (C) C (C (NCCN (CC) CC) =O) =C (C) N3
Molecular Formula
C22H27FN4O2
Molecular Weight
398.47
References & Citations
Ryan Tsz-Hei Tse 1, Christine Yim-Ping Wong 1, Xiaofan Ding 2, Carol Ka-Lo Cheng 1, Chit Chow 3, Ronald Cheong-Kin Chan 3, Joshua Hoi-Yan Ng 4, Victor Wai-Lun Tang 4, Peter Ka-Fung Chiu 1, Jeremy Yuen-Chun Teoh 1, Nathalie Wong 2, Ka-Fai To 3, Chi-Fai Ng The establishment of kidney cancer organoid line in drug testing Cancer Med, (2024)
Pubmed id
38923304
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
